Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAV-RAPA
2024-516001-23-00Phase 2Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in arteriovenous malformation (AVM), sponsored by CHU Amiens-Picardie. Primary endpoint: Proportion of patients with ≥30% reduction in AVM tumor volume at 1 year. Planned start Jan 2025; status: authorised.
02
Drugs
sirolimus
03
Conditions
arteriovenous malformation (AVM)
Beyond the preview
Go deeper on 2024-516001-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516001-23-00.